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Abstract. Software failure in the medical device domain can lead to injury or 
death. Controlling this risk is fundamental to producing quality software. To 
produce quality software, an effective requirements and hazards traceability 
process is required. Hence traceability is central to medical device software de-
velopment. It is also an essential requirement for regulatory approval. The ne-
cessity for traceability is reinforced by the medical device standards and guide-
lines. In this paper we outline how traceability is an important part of medical 
device software development, what standards contain reference to traceability, 
and which specific clauses within those standards companies should refer to 
when defining their  traceability processes. We also summarise the findings ob-
tained when  a lightweight assessment method (Med-Trace), that we created, 
based upon the traceability practices within these standards, was  implemented 
in two SME organizations.    
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1 Introduction: Background to Medical device software 
Software-based medical devices are playing an increasingly important part in 
healthcare. Many medical devices must interface with other equipment, connect to 
hospital and laboratory information systems, and work in high-stress situations. The 
increased demands on such devices has resulted in increased software complexity and 
has created formidable development challenges for their manufacturers [1]. This 
increased complexity has resulted in the need for increased traceability and risk 
control measures. 
In order to market their devices within a country, a medical device development com-
pany must comply with the regulatory requirements of that country [2]. Although 
guidance exists from regulatory bodies on what software activities must be per-
formed, no specific method for performing these activities is outlined or enforced [3]. 
In 1993 the European Council released Medical Device Directive (MDD) 93/42/EC 
[4]. The purpose of this directive was to ensure the safety of medical devices placed 
on the European market. This directive has been amended by Directives 2000/70/EC 
[5], 2001/104/EC [6], 2003/32/EC [7] and 2007/47/EC [8]. 
To this end, in the USA, the Food and Drug Administration (FDA) Center for Devices 
and Radiological Health (CDRH), independently from the European Council, pub-
lished guidance papers which include risk based activities to be performed when us-
ing off-the-shelf software [9],  during software validation [10], and for pre-market 
submission [11]. These documents however did not enforce any specific activity for 
performing the software activities, hence manufacturers could fail to comply with 
expected requirements. 
Therefore the medical device industry decided to recognise ISO/IEC 12207 [12] (gen-
eral software engineering process standard) as suitable for general medical device 
software development. However the Association for the Advancement of Medical 
Instrumentation (AAMI) identified pitfalls in ISO/IEC 12207 and produced AAMI 
SW68 [13] (Medical Device- Software Lifecycle Processes) which was based on 
ISO/IEC 12207. In 2006 a new standard AAMI/IEC 62304 [14] was released which 
replaced AAMI SW68. 
The remainder of this paper is structured as follows; Section 2  discusses the impor-
tance of traceability in all domains culminating with the medical device domain. Sec-
tion 3 identifies traceability requirements within the medical device standards. Section 
4 considers the implementation and findings of Med-trace, a traceability assessment 
model. In Section 5 we draw our conclusions. 
2 Traceability  
2.1 Introduction 
In engineering terms a trace is comprised of a source artifact, a target artifact and the 
link between them [15]. Traceability is the ability to establish and use these traces. 
Numerous definitions for traceability exist in the literature but one of the most popu-
lar and encompassing is: 
"Requirements traceability refers to the ability to describe and follow the life 
of a requirement, in both a forwards and backwards direction (i.e., from its 
origins through its development and specification to its subsequent deploy-
ment and use, and through all periods of on-going refinement and iteration 
in any of these phases "[16]. 
In general, traceability is about understanding a design right through from the origin 
of the requirement to its implementation, test and maintenance. Traceability allows us 
to understand aspects such as to whether the customers’ requirements are being met, 
the specific requirements that an artefact relates to, and the origins and motivation of 
a requirement.  Traceability helps ensure that ‘quality’ software is developed. 
2.2 Traceability in all domains 
Software systems are becoming increasingly complex. Artefacts such as test cases, 
requirements documents, source code, design documents, bug reports etc, and the 
links between them are created over long periods of time by different people. Creating 
and maintaining these links is a difficult and expensive task. Therefore most existing 
software systems lack explicit traceability links between artefacts [17]. 
Traceability was initially used to trace requirements from their source to implementa-
tion and test, but now plays an increasing role in defect management, change man-
agement and project management. Increasingly software development is globally 
distributed across multiple teams and sites which makes traceability even more impor-
tant [18]. As traceability provides an essential support for developing high quality 
software systems [19], it is vital to engage an efficient traceability process. 
Traceability implementation is mandated in many software development standards 
and many industries, in particular the safety critical industries [20]. For example in 
the US the Food and  Drugs Administration states that code must be linked to re-
quirements and test cases. Safety critical products can be dangerous because failure 
can result in loss of life, significant environmental damage, or major financial loss 
[21]. Safety critical systems must satisfy a range of functional and non-functional 
requirements, including safety, reliability and availability. Regulation normally re-
quires safety critical systems are certified before entering service. This involves sub-
mission to the appropriate regulator of a safety case (a reasoned argument that safety 
requirements have been met and the system is acceptably safe to operate) must be 
made for a safety critical systems as regulation requires these systems are certified 
before entering service [22]. 
2.3 Traceability in the  medical device domain 
In the medical device domain, software development is a difficult and complex en-
deavor. Defective medical device software can cause serious injury or death. There-
fore safety is a key concern [18]. In the period from 7th Feb 2011 and 7th Feb 2012 the 
FDA recorded 151 medical device recalls and state software as the cause [23]. The 
number of devices that have recently been recalled due to software and hardware 
problems is increasing at an alarming rate [24]. During 2009 the FDA recalled 63 
medical devices because of software issues. During 2010 they recalled 107 medical 
devices for the same reason. 
It is incumbent on medical device manufacturers to ensure, to the best of their ability, 
that software-based medical devices are safe and effective. Meeting this responsibility 
requires expertise in effective risk management practices, familiarity with software 
safety, and the adoption of a risk management mind-set [1]. Manufacturers must es-
tablish effective software development processes that are based on recognized engi-
neering principles appropriate for safety critical systems. At the heart of such proc-
esses, they must incorporate traceability. 
Generally there is a lack of published material regarding traceability in medical de-
vice software in addition to a lack of guidance on how to implement traceability ef-
fectively in organisations [18]. As traceability is central to the development of medi-
cal device software, a traceability assessment and improvement method called Med-
Trace [20] has been developed (See section 4).  
3 Medical device software standards and guidelines 
Software traceability is central to medical device software development and essential 
for regulatory compliance. The need for this compliance is highlighted in many of the 
medical device software standards and guidelines. In order to understand the generic 
requirements for traceability and in particular the requirements for traceability within 
the medical device domain, a literature review of generic, safety critical and medical 
device domains was conducted. Detailed requirements for traceability, as expressed 
by the medical device standards and guidelines, are summarised in this section. Table 
1, details the number of times (including  section numbers for each instance) each 
standard identifies traceability. Table 2 provides an example of two of these 
references. 
 
Table 1: Number of times (and section numbers) each standard impacts traceability 
Standard Title  No. Section Numbers 
ANSI/AAMI/IEC 62304:2006 Medical device 
software—Software life cycle processes (2006) 
6 5.1.1;   5.2.6;   5.7.4;   
7.3.3;  8.2.4;      B.6.2;    
Medical Device Directive 2007/47/EC 1 ANNEX I 12.1 
General Principles of Software Validation ; U.S. 
Food and Drug Administration 2002 
6 3.1.2; 3.2; 5.2.2;     
5.2.3;   5.2.4;    5.2.5; 
Guidance for the Content of Premarket Submis-
sions for Software Contained in Medical Devices 
: US FDA 2005 
2 Page 11;   Page 16; 
Off-The-Shelf Software Use in Medical Devices: 
US FDA 1999 
1 5.5.1 
ISO 14971:2007(E) - Medical devices — Applica-
tion of risk management to medical devices  
1 3.5; 
IEC/TR 80002-1:2009 - Medical device software 
Part 1: Guidance on the application of ISO 14971 
8 3.5;    6.3;     Table C;  
Table D 
ISO 13485 (2003) Medical devices — Quality 
management systems — Requirements for regula-
tory purposes 
2 7.5.3.2.1;     7.5.3.2.2; 
 
 
 
 
 
 
 
 
 
 Table 2: An example of Practice content relating to traceability taken from two standards 
as referred to in Table 1 
Standard Title Process Practice Practice Content 
ANSI/AAMI/IE
C 62304:2006 
Medical device 
software—
Software life 
cycle processes 
(2006) 
Software 
develop-
ment Pro-
cess 
5.0 
Software 
development 
planning 
5.1 
Software 
development 
Plan  5.1.1 
The manufacturer shall establish a 
software development plan which 
should ensure TRACEABILITY be-
tween SYSTEM requirements, soft-
ware requirements, SOFTWARE 
SYSTEM test, and RISK CONTROL 
measures implemented in software; 
ANSI/AAMI/IE
C 62304:2006 
Software 
configura-
tion man-
agement 
process 
8.0 
Change con-
trol 
8.2 
 
Traceability 
change7.3.3 
The MANUFACTURER shall create 
an audit trail whereby each: a) 
CHANGE REQUEST; b) relevant 
PROBLEM REPORT; and c) approval 
of the CHANGE REQUEST can be 
traced. [Class A, B, C] 
 
Failure in medical device software can have fatal consequences. The gravity of these 
consequences is highlighted in the medical device standards through reiteration of the 
necessity to control risks. Traceability can control risk. For example the General 
Principles of Software Validation (GPSV) [10] states that a software requirements 
traceability analysis should be conducted to trace software requirements to (and from) 
system requirements and to risk analysis results. Moreover ISO 14971:2007 [25] 
requires the manufacturer to establish and maintain a risk control file which shall 
provide traceability for each identified hazard to a)risk analysis, b)risk evaluation, 
c)implementation and verification of risk control measures and d)the assessment of 
the acceptability of any residual risks. The documentation of risk control measures is 
emphasised by ANSI/AAMI/IEC 62304 [14]which directs the manufacturer to 
document traceability of the software hazards: from hazard situation to software item; 
from the software item to the specific software cause; from the software cause to the 
risk control measure; and from the risk control measure to the verification of the risk 
control measure. The imperative for risk control is further called for in Off-The-Shelf 
Software Use in Medical Devices [9], Guidance for the Content of Premarket 
Submissions for Software Contained in Medical Devices [11] and IEC/TR 80002-
1 [26] . 
There is considerable variance in the level of traceability detail required within the 
standards. Some of the standards provide very little detail as to between which stages 
of the Software Development Life Cycle (SDLC) traceability should be provided e.g. 
ISO 13485 requires an organization to establish documented procedures for traceabil-
ity and that such procedures shall define the extent of product traceability and the 
records required. However other standards provide a greater level of required trace-
ability detail such as GPSV which requires traceability from system requirements to 
software requirements and through each stage of the SDLC including design, code 
(including modules and functions) and test (traceability from test to detail design, 
high level design and to software requirements).  Moreover the Guidance for the 
Content of Premarket Submissions for Software Contained in Medical Devices 
state that explicit traceability must exist among requirements, specifications, identi-
fied hazards and mitigations and among verification and validation testing. 
The ability to trace change is good practice for software development in general 
and of necessity for medical device software development. The necessity for change 
management is emphasised in ANSI/AAMI/IEC 62304 when it states that the manu-
facturer shall create an audit trail whereby each a)Change request b)Problem report 
and c)Approval of change request, can be traced. It further requires that approved 
change requests are made traceable to the actual modification and verification of the 
software. 
 
4 Med-Trace assessments and findings 
4.1 Development of the Med-Trace Assessment Method 
Due to the safety critical nature of medical device software, a company must meet 
‘country specific’ regulatory requirements in order to market their product in that 
country. An effective traceability process is a crucial requirement to achieving regula-
tory compliance. Due to a lack of specific guidance within the medical device stand-
ards and documentation, achieving an effective traceability process is problematic, 
resulting in many medical device companies engaging inefficient traceability process-
es [20]. Consequently, a method (known as Med-Trace [20]) of assisting medical 
device software companies to improve their traceability processes and to to adhere to 
the traceability aspects of the medical device software standards (as detailed in sec-
tion 3) was developed. Med-Trace is a lightweight software traceability process as-
sessment and improvement method for the medical device industry. Med-Trace is 
based on traceability best practices emanating from software engineering process 
models (CMMI_R, ISO/IEC 15504-5), software engineering traceability literature and 
medical device software standards and guidelines i.e. the traceability practices that are 
expressed in table 1.  
4.2 Med-Trace Implementation and observations 
 
This section discusses how the Med-Trace assessment method was implemented in 
two medical device organizations and the resulting observations. The objectives of the 
case studies were to demonstrate how Med-Trace could be used to assess the current 
status of the software traceability processes within similar organisations and to dis-
cover the main problems that medical device software development organizations 
face in terms of traceability. 
Med-Trace was implemented in two Small to Medium Sized (SME) medical device 
organisations. Both organisations developed electronic based medical devices that 
require compliance with both the FDA and the MDD. One organisation was based in 
Ireland while the other was based in the UK. 
From the Med-Trace assessment the following observations were made across both 
organisations: 
 A member of management was responsible for implementing traceability and its 
importance in medical device software development was recognised and under-
stood. 
 Tracing requirements and managing risk was recognised as difficult and complex. 
 There is a lack of detailed guidance on how to implement traceability. 
 Their process for software development with regard to traceability needed to be 
improved and formulised. 
 The requirement for relevant training and the ability to record and leverage best 
practice with regard to traceability also emerged. 
 The need for automated tools to manage traceability was recognised as was the 
serious limitation of using manual tools.  
 Financial constraints needed to be considered when adapting automated tools. 
Both organisations considered Med-Trace to be worthwhile and very relevant and 
appreciated the fact the Med-Trace is lightweight. The findings report addressed key 
areas where improvements were required and both organisations agreed to adapt the 
resultant traceability process improvement plan and agreed to be reassessed. 
6       Conclusions and Future Work 
An effective traceability process is essential when developing medical device soft-
ware due to its safety critical nature. The requirement for effective traceability is 
mandated by the medical device standards and guidelines and its importance is evi-
dent from the number of times traceability is referred to in these standards and guide-
lines. However, the implementation of an effective traceability process is recognised 
as difficult and complex. 
While effective traceability is mandated by the standards and its necessity was under-
stood by the two organisations who participated in the Med-Trace assessment, there is 
a lack of detailed guidance in how to best implement an effective traceability process 
within the medical device software domain. There currently are a challenging number 
of standards governing medical device software development and to determine the 
exact traceability requirement from each of these standards can be time consuming. 
Med-Trace addresses these challenges by providing a light weight assessment method 
which may be used to diagnose an organization’s strengths and weaknesses in relation 
to traceability in their software development processes. 
The limitations (slow, tedious and prone to error) of using manual traceability tools 
such as Excel is an issue that needs addressing. Automated tools mitigate these limita-
tions to some extent, however there are concerns around these tools such as cost, 
missing traces, needless traces, training, and the fact that tools require validation in 
their own right. Automated tools alone don’t provide for accountability and so human 
intervention in safety critical domains such as medical device software development 
is necessary. The limitations of existing automated traceability tools imply the need 
for further development of effective tools for SME organisations operating in the 
safety critical domain. 
To-date, Med-Trace has been applied in two SME organisations and has been well 
received. It is envisaged that Med-Trace will continue to be refined based on ongoing 
research and feedback from future assessments. Future plans include a tool to auto-
mate Med-Trace with the objective of facilitating its national and international roll out 
and to encourage its wider use. 
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